Pepcid

Pepcid is a brand name of famotidine, approved by the FDA in the following formulation(s):

PEPCID (famotidine - for suspension; oral)

• 
  Manufacturer: SALIX PHARMS
  
  Approval date: February 2, 1987
  
  Strength(s): 40MG/5ML ^[RLD][AB]

PEPCID (famotidine - tablet; oral)

• 
  Manufacturer: MARATHON PHARMS
  
  Approval date: October 15, 1986
  
  Strength(s): 20MG ^[AB], 40MG ^[RLD][AB]

Has a generic version of Pepcid been approved?

Yes. The following products are equivalent to Pepcid:

famotidine for suspension; oral

• 
  Manufacturer: LUPIN LTD
  
  Approval date: June 29, 2010
  
  Strength(s): 40MG/5ML ^[AB]


• 
  Manufacturer: NAVINTA LLC
  
  Approval date: May 27, 2010
  
  Strength(s): 40MG/5ML ^[AB]

famotidine tablet; oral

• 
  Manufacturer: ALEMBIC PHARMS LTD
  
  Approval date: May 22, 2009
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: APOTEX
  
  Approval date: July 23, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: CARLSBAD
  
  Approval date: April 16, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: April 16, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: IVAX SUB TEVA PHARMS
  
  Approval date: April 16, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: April 16, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: April 18, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: PERRIGO
  
  Approval date: July 27, 2005
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: May 10, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: April 16, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: April 16, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]


• 
  Manufacturer: WOCKHARDT
  
  Approval date: April 16, 2001
  
  Strength(s): 20MG ^[AB], 40MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pepcid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Pepcid.

See also...

• Pepcid Consumer Information (Drugs.com)
• Pepcid Consumer Information (Wolters Kluwer)
• Pepcid Solution Consumer Information (Wolters Kluwer)
• Pepcid Consumer Information (Cerner Multum)
• Pepcid Advanced Consumer Information (Micromedex)
• Pepcid AHFS DI Monographs (ASHP)
• Famotidine Consumer Information (Drugs.com)
• Famotidine Consumer Information (Wolters Kluwer)
• Famotidine Chewable Tablets Consumer Information (Wolters Kluwer)
• Famotidine Solution Consumer Information (Wolters Kluwer)
• Famotidine Suspension Consumer Information (Wolters Kluwer)
• Famotidine Consumer Information (Cerner Multum)
• Famotidine Advanced Consumer Information (Micromedex)
• Famotidine AHFS DI Monographs (ASHP)

H.P. Acthar Gel

H.P. Acthar Gel is a brand name of corticotropin, approved by the FDA in the following formulation(s):

H.P. ACTHAR GEL (corticotropin - injectable; injection)

• 
  Manufacturer: QUESTCOR PHARMS
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 80 UNITS/ML ^[RLD]

Has a generic version of H.P. Acthar Gel been approved?

No. There is currently no therapeutically equivalent version of H.P. Acthar Gel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of H.P. Acthar Gel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with H.P. Acthar Gel.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 15, 2017 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• HP Acthar Gel Consumer Information (Wolters Kluwer)
• Acthar Gel, H.P. Consumer Information (Cerner Multum)
• H.P. Acthar Gel AHFS DI Monographs (ASHP)
• Corticotropin Gel Consumer Information (Wolters Kluwer)
• Corticotropin Consumer Information (Cerner Multum)
• H.P. Acthar Advanced Consumer Information (Micromedex)
• Corticotropin Injection Advanced Consumer Information (Micromedex)
• Corticotropin AHFS DI Monographs (ASHP)
• Corticotropin (Anti-inflammatory) AHFS DI Monographs (ASHP)

Thalitone

Thalitone is a brand name of chlorthalidone, approved by the FDA in the following formulation(s):

THALITONE (chlorthalidone - tablet; oral)

• 
  Manufacturer: MONARCH PHARMS
  
  Approval date: December 20, 1988
  
  Strength(s): 15MG ^[RLD]

Has a generic version of Thalitone been approved?

No. There is currently no therapeutically equivalent version of Thalitone available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Thalitone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Thalitone.

See also...

• Thalitone Consumer Information (Wolters Kluwer)
• Thalitone Consumer Information (Cerner Multum)
• Thalitone Advanced Consumer Information (Micromedex)
• Thalitone AHFS DI Monographs (ASHP)
• Chlorthalidone Consumer Information (Wolters Kluwer)
• Chlorthalidone Consumer Information (Cerner Multum)
• Chlorthalidone Advanced Consumer Information (Micromedex)
• Chlorthalidone AHFS DI Monographs (ASHP)

Anaprox-DS

See also: Generic Anaprox

Anaprox-DS is a brand name of naproxen, approved by the FDA in the following formulation(s):

ANAPROX DS (naproxen sodium - tablet; oral)

• 
  Manufacturer: ROCHE PALO
  
  Approval date: September 30, 1987
  
  Strength(s): EQ 500MG BASE ^[RLD][AB]

Has a generic version of Anaprox-DS been approved?

Yes. The following products are equivalent to Anaprox-DS:

naproxen sodium tablet; oral

• 
  Manufacturer: AMNEAL PHARMS NY
  
  Approval date: April 25, 2007
  
  Strength(s): EQ 500MG BASE ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA LTD
  
  Approval date: October 31, 2011
  
  Strength(s): EQ 500MG BASE ^[AB]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: July 26, 2007
  
  Strength(s): EQ 500MG BASE ^[AB]


• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: April 27, 2007
  
  Strength(s): EQ 500MG BASE ^[AB]


• 
  Manufacturer: HIKMA
  
  Approval date: May 14, 1996
  
  Strength(s): EQ 500MG BASE ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: December 21, 1993
  
  Strength(s): EQ 500MG BASE ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: May 31, 1995
  
  Strength(s): EQ 500MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anaprox-DS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Anaprox-DS.

See also...

• Anaprox-DS Consumer Information (Cerner Multum)
• Anaprox DS Advanced Consumer Information (Micromedex)
• Naproxen Consumer Information (Drugs.com)
• Naproxen Consumer Information (Wolters Kluwer)
• Naproxen Enteric-Coated Tablets Consumer Information (Wolters Kluwer)
• Naproxen Suspension Consumer Information (Wolters Kluwer)
• Naproxen Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Naprelan 375 Consumer Information (Cerner Multum)
• Naprelan 500 Consumer Information (Cerner Multum)
• Naprelan 750 Consumer Information (Cerner Multum)
• Naproxen Consumer Information (Cerner Multum)
• Naprelan 500 Advanced Consumer Information (Micromedex)
• Naprelan Dose Card Advanced Consumer Information (Micromedex)
• Naxen Advanced Consumer Information (Micromedex)
• Naproxen Advanced Consumer Information (Micromedex)
• Naproxen AHFS DI Monographs (ASHP)
• Naproxen Sodium AHFS DI Monographs (ASHP)

Acuvail

Acuvail is a brand name of ketorolac ophthalmic, approved by the FDA in the following formulation(s):

ACUVAIL (ketorolac tromethamine - solution/drops; ophthalmic)

• 
  Manufacturer: ALLERGAN
  
  Approval date: July 22, 2009
  
  Strength(s): 0.45% ^[RLD]

Has a generic version of Acuvail been approved?

No. There is currently no therapeutically equivalent version of Acuvail available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Acuvail. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Ketorolac tromethamine compositions for treating ocular pain
  Patent 7,842,714
  Issued: November 30, 2010
  Inventor(s): Farnes; Eldon Q. & Attar; Mayssa & Schiffman; Rhett M. & Chang; Chin-Ming & Graham; Richard S. & Welty; Devin F.
  Assignee(s): Allergan, Inc.
  The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
  
  Patent expiration dates:
  
  
  • August 15, 2029
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 22, 2012 - NEW PRODUCT
  
  

See also...

• Acuvail Consumer Information (Drugs.com)
• Acuvail Drops Consumer Information (Wolters Kluwer)
• Acuvail Consumer Information (Cerner Multum)
• Acuvail Advanced Consumer Information (Micromedex)
• Ketorolac Drops Consumer Information (Wolters Kluwer)
• Ketorolac Tromethamine Drops Consumer Information (Wolters Kluwer)
• Ketorolac ophthalmic Consumer Information (Cerner Multum)
• Ketorolac Ophthalmic Advanced Consumer Information (Micromedex)
• Ketorolac Tromethamine eent AHFS DI Monographs (ASHP)

Ofirmev

Ofirmev is a brand name of acetaminophen, approved by the FDA in the following formulation(s):

OFIRMEV (acetaminophen - solution; iv (infusion))

• 
  Manufacturer: CADENCE PHARMS
  
  Approval date: November 2, 2010
  
  Strength(s): 1000MG/100ML (10MG/ML) ^[RLD]

Has a generic version of Ofirmev been approved?

No. There is currently no therapeutically equivalent version of Ofirmev available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ofirmev. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stable liquid paracetamol compositions, and method for preparing same
  Patent 6,028,222
  Issued: February 22, 2000
  Inventor(s): Dietlin; Francois & Fredj; Daniele
  Assignee(s): SCR Pharmatop
  Novel stable paracetamol compositions for use in therapeutic chemistry and specifically galenic pharmacy are disclosed. The compositions contain a solution of paracetamol in an aqueous solvent combined with a buffer having a pH of 4 to 8, and a free radical capturing agent. A water-insoluble inert gas is carefully bubbled through the aqueous solvent to remove oxygen from the medium. Said compositions may also be combined with a centrally or peripherally acting analgesic agent, and are provided as injectable compositions for relieving pain.
  
  Patent expiration dates:
  
  
  • August 5, 2017
    
    ✓ 
    Drug product
  
  



• 
  Method for obtaining aqueous formulations of oxidation-sensitive active principles
  Patent 6,992,218
  Issued: January 31, 2006
  Inventor(s): Dietlin; Francois & Fredj; Daniele
  Assignee(s): Pharmatop SCR
  A method for obtaining aqueous formulations with easily oxidizable active principles, notably phenols, stable over a prolonged period, comprising subjecting them to extreme deoxygenation by bubbling with an inert gas and/or placing wider vaccum, protecting them against possible resorption of oxygen by keeping them under an inert gas atmosphere, by filling, under inert gas, into bottles previously cleared of air by insufflation with inert gas, then subjecting them, while stoppering, to low pressure as obtained in the bottle, of 65,000 Pa maximum, to obtain aqueous solutions having a residual oxygen concentration in the solution below 2 ppm, and preferably of the order of 1 ppm and even 0.5 ppm useful as injectable preparations having an oxygen concentration in the solution below 2 ppm.
  
  Patent expiration dates:
  
  
  • June 6, 2021
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 2, 2013 - NEW PRODUCT
  
  

See also...

• Ofirmev Consumer Information (Drugs.com)
• Ofirmev Injection Consumer Information (Wolters Kluwer)
• Ofirmev Advanced Consumer Information (Micromedex)
• Acetaminophen Consumer Information (Drugs.com)
• Acetaminophen Capsules Consumer Information (Wolters Kluwer)
• Acetaminophen Chewable Tablets Consumer Information (Wolters Kluwer)
• Acetaminophen Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Acetaminophen Dispersible Tablets Consumer Information (Wolters Kluwer)
• Acetaminophen Drops Consumer Information (Wolters Kluwer)
• Acetaminophen Elixir Consumer Information (Wolters Kluwer)
• Acetaminophen Gel Syrup Consumer Information (Wolters Kluwer)
• Acetaminophen Injection Consumer Information (Wolters Kluwer)
• Acetaminophen Suppositories Consumer Information (Wolters Kluwer)
• Acetaminophen Suspension Consumer Information (Wolters Kluwer)
• Acetaminophen Suspension Drops Consumer Information (Wolters Kluwer)
• Tempra 1 Drops Consumer Information (Wolters Kluwer)
• Acetaminophen Quickmelt Consumer Information (Cerner Multum)
• Mapap Infants' Consumer Information (Cerner Multum)
• Tylenol Arthritis Gelcap Consumer Information (Cerner Multum)
• Acetaminophen Consumer Information (Cerner Multum)
• Acetaminophen rectal Consumer Information (Cerner Multum)
• Children's Acetaminophen Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Bubble Gum Flavor Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Cherry Flavor Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Grape Flavor Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Suspension Bubble Gum Flavor - Ages 2 To 11 Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Suspension Cherry Flavor Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Suspension Grape Flavor - Ages 2 To 11 Advanced Consumer Information (Micromedex)
• Comtrex Sore Throat Relief Advanced Consumer Information (Micromedex)
• Acetaminophen Intravenous Advanced Consumer Information (Micromedex)
• Acetaminophen Oral, Rectal Advanced Consumer Information (Micromedex)
• Acetaminophen, sodium bicarbonate, and citric acid Advanced Consumer Information (Micromedex)
• Acetaminophen AHFS DI Monographs (ASHP)

Omnipaque 240

See also: Generic Omnipaque 140, Generic Omnipaque 180, Generic Omnipaque 300, Generic Omnipaque 350

Omnipaque 240 is a brand name of iohexol, approved by the FDA in the following formulation(s):

OMNIPAQUE 240 (iohexol - solution; injection, oral, rectal)

• 
  Manufacturer: GE HEALTHCARE
  
  Approval date: December 26, 1985
  
  Strength(s): 51.8% ^[RLD]


• 
  Manufacturer: GE HEALTHCARE
  
  Approval date: October 24, 1995
  
  Strength(s): 51.8%
  

Has a generic version of Omnipaque 240 been approved?

No. There is currently no therapeutically equivalent version of Omnipaque 240 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Omnipaque 240. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Omnipaque 240.

See also...